Illumina completes Grail acquisition, regulators be damned
Despite looming antitrust investigations on both sides of the Atlantic, Illumina has pushed forward with finalizing its $8 billion deal to acquire Grail, maker of a newly launched blood test to detect dozens of different cancers.